Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lexicon Share Spike On Carcinoid Syndrome Phase III Data

This article was originally published in Scrip

Executive Summary

Lexicon Pharmaceuticals Inc. is looking forward to filing its first US NDA after announcing positive top-line Phase III data for its lead product, telotristat etiprate, in treating cancer patients with carcinoid syndrome inadequately controlled by the current standard of care. Shares in the firm shot up by 47% to $12.41 on NASDAQ the morning of Aug. 1, 2015 following the news.

You may also be interested in...



Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.

AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes

A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.

Weak Spots Blight Novartis Third Quarter As New Products Shine

A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel